Prof Michael A Laffan

Publications


Journals

  • McKinnon TA; Nowak A; Cutler J; Riddell FA; Laffan MA; Millar C. (26 Apr 2012). Characterisation of von Willebrand factor A1 domain mutants I1416N and I1416T: correlation of clinical phenotype with flow-based platelet adhesion. J Thromb Haemost. DOI.
  • Shapiro S; Laffan M. (27 Apr 2012). Making contact with microparticles. J Thromb Haemost. DOI.
  • Neelakantan P; Marin D; Laffan M; Goldman J; Apperley J; Milojkovic D. (24 Apr 2012). Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy. Haematologica. DOI.
  • Nowak AA; Canis K; Riddell A; Laffan MA; McKinnon TA. (19 Apr 2012). O-linked glycosylation of von Willebrand factor modulates the interaction with platelet receptor glycoprotein Ib under static and shear stress conditions. Blood. DOI.
  • Livesey JA; Manning RA; Meek J; Jackson JE; Kulinskaya E; Laffan MA; Shovlin CL. (2011). Low serum iron levels are associated with elevated serum levels of coagulation factor VIII and pulmonary emboli/deep venous thromboses in replicate cohorts of hereditary haemorrhagic telangiectasia patients. Thorax.
  • Mahlangu JN; Coetzee MJ; Laffan M; Windyga J; Yee TT; Schroeder J; Haaning J; Siegel JE; et alLemm G. (May 2012). Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia. J Thromb Haemost. 10:773-780. DOI.
  • Livesey JA; Manning RA; Meek JH; Jackson JE; Kulinskaya E; Laffan MA; Shovlin CL. (Apr 2012). Low serum iron levels are associated with elevated plasma levels of coagulation factor VIII and pulmonary emboli/deep venous thromboses in replicate cohorts of patients with hereditary haemorrhagic telangiectasia. Thorax. 67:328-333. DOI.
  • Ranger A; Manning RA; Lyall H; Laffan MA; Millar CM. (May 2012). Pregnancy in type 2B VWD: a case series. Haemophilia. 18:406-412. DOI.
  • Beltrán-Miranda CP; Luna-Záizar H; López-Jiménez JJ; Mantilla-Capacho JM; Laffan M; Jaloma-Cruz AR. (Jan 2012). Phenotypic variability in a family with haemophilia B and prothrombin G20210A. Haemophilia. 18:e22-e23. DOI.
  • Bentley P; Rosso M; Sadnicka A; Israeli-Korn S; Laffan M; Sharma P. (18 Jul 2011). Intravenous immunoglobulin increases plasma viscosity without parallel rise in blood pressure. J Clin Pharm Ther. DOI.
  • Patel A; Cooper N; Laffan MA. (Feb 2011). Safety of Recombinant Activated Factor VII in Randomized Clinical Trials. The New England Journal of Medicine. 364:574.
  • Tsiara S; Pappas K; Boutsis D; Laffan M. (Jan 2011). New oral anticoagulants: should they replace heparins and warfarin?. Hellenic J Cardiol. 52:52-67.
  • Starke RD; Ferraro F; Paschalaki KE; Dryden NH; McKinnon TA; Sutton RE; Payne EM; Haskard DO; et alHughes AD; Cutler DF; Laffan MA; Randi AM. (20 Jan 2011). Endothelial von Willebrand factor regulates angiogenesis. Blood. 117:1071-1080. DOI.
  • Collins PW; Baglin TP; Dang R; Evans G; Greaves M; Laffan M; Pasi KJ; Rose P; et alStanworth S; Toh CH; Gower J. (1 Sep 2010). Non-malignant haematology research in the UK: looking forward to new opportunities. BRITISH JOURNAL OF HAEMATOLOGY. 150:732-736. DOI.
  • Stanworth SJ; Grant-Casey J; Lowe D; Laffan M; New H; Murphy MF; Allard S. (Jan 2011). The use of fresh-frozen plasma in England: high levels of inappropriate use in adults and children. Transfusion. 51:62-70. DOI.
  • McKinnon TA; Goode EC; Birdsey GM; Nowak AA; Chan AC; Lane DA; Laffan MA. (29 Jul 2010). Specific N-linked glycosylation sites modulate synthesis and secretion of von Willebrand factor. Blood. 116:640-648. DOI.
  • Wong CL; Szydlo R; Gibbs S; Laffan M. (1 Apr 2010). Hereditary and acquired thrombotic risk factors for chronic thromboembolic pulmonary hypertension. BLOOD COAGULATION & FIBRINOLYSIS. 21:201-206. Author weblink DOI.
  • Uprichard J; Manning RA; Laffan MA. (May 2010). Monitoring heparin anticoagulation in the acute phase response. Br J Haematol. 149:613-619. DOI.
  • Shovlin CL; Angus G; Manning RA; Okoli GN; Govani FS; Elderfield K; Birdsey GM; Mollet IG; et alLaffan MA; Mauri FA. (2010). Endothelial cell processing and alternatively spliced transcripts of factor VIII: potential implications for coagulation cascades and pulmonary hypertension. PLoS One. 5:e9154. DOI.
  • Canis K; McKinnon TA; Nowak A; Panico M; Morris HR; Laffan M; Dell A. (Jan 2010). The plasma von Willebrand factor O-glycome comprises a surprising variety of structures including ABH antigens and disialosyl motifs. J Thromb Haemost. 8:137-145. DOI.
  • McGrath RT; McKinnon TA; Byrne B; O'Kennedy R; Terraube V; McRae E; Preston RJ; Laffan MA; et alO'Donnell JS. (1 Apr 2010). Expression of terminal alpha2-6-linked sialic acid on von Willebrand factor specifically enhances proteolysis by ADAMTS13. Blood. 115:2666-2673. DOI.
  • Riddell AF; Gomez K; Millar CM; Mellars G; Gill S; Brown SA; Sutherland M; Laffan MA; et alMcKinnon TA. (15 Oct 2009). Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of von Willebrand factor. Blood. 114:3489-3496. DOI.
  • Zanardelli S; Chion AC; Groot E; Lenting PJ; McKinnon TA; Laffan MA; Tseng M; Lane DA. (24 Sep 2009). A novel binding site for ADAMTS13 constitutively exposed on the surface of globular VWF. Blood. 114:2819-2828. DOI.
  • Perry D; Berntorp E; Tait C; Dolan G; Holme PA; Laffan M; Lassila R; Mumford A; et alPasi J; Wilde J; Will A; Yee TT. (1 Jan 2010). FEIBA prophylaxis in haemophilia patients: a clinical update and treatment recommendations. HAEMOPHILIA. 16:80-89. Author weblink DOI.
  • Uprichard J; Dazzi F; Apperley JF; Laffan MA. (1 Jan 2010). Haemopoietic stem cell transplantation induces tolerance to donor antigens but not to foreign FVIII peptides. HAEMOPHILIA. 16:143-147. Author weblink DOI.
  • Laffan M; Mckinnon TAJ. (1 Jul 2009). Blocking von Willebrand factor: a novel anti-platelet therapy. JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 7:1152-1154. Author weblink DOI.
  • Collins PW; Mathias M; Hanley J; Keeling D; Keenan R; Laffan M; Perry D; Liesner R; et alUK Haemophilia Centre Doctors' Organisation. (May 2009). Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort. J Thromb Haemost. 7:787-794. DOI.
  • McDonald V; Laffan M; Benjamin S; Bevan D; Machin S; Scully MA. (1 Feb 2009). Thrombotic thrombocytopenic purpura precipitated by acute pancreatitis: a report of seven cases from a regional UK TTP registry. BRITISH JOURNAL OF HAEMATOLOGY. 144:430-433. Author weblink DOI.
  • Sirker A; Malik N; Bellamy M; Laffan MA. (1 Jun 2008). Acute myocardial infarction following tranexamic acid use in a low cardiovascular risk setting. BRITISH JOURNAL OF HAEMATOLOGY. 141:907-908. Author weblink DOI.
  • Sohal M; Laffan M. (1 Jul 2008). Von Willebrand disease and angiodysplasia responding to atorvastatin. BRITISH JOURNAL OF HAEMATOLOGY. 142:308-309. Author weblink DOI.
  • Ghevaert C; Salsmann A; Watkins NA; Schaffner-Reckinger E; Rankin A; Garner SF; Stephens J; Smith GA; et alDebili N; Vainchenker W; de Groot PG; Huntington JA; Laffan M; Kieffer N; Ouwehand WH. (1 Apr 2008). A nonsynonymous SNP in the ITGB3 gene disrupts the conserved membrane-proximal cytoplasmic salt bridge in the alpha(IIb)beta(3) integrin and cosegregates dominantly with abnormal proplatelet formation and macrothrombocytopenia. BLOOD. 111:3407-3414. Author weblink DOI.
  • McKinnon TA; Chion AC; Millington AJ; Lane DA; Laffan MA. (15 Mar 2008). N-linked glycosylation of VWF modulates its interaction with ADAMTS13. Blood. 111:3042-3049. DOI.
  • Pepper RJ; Gale DP; Wajed J; Bommayya G; Ashby D; McLean A; Laffan M; Maxwell PH. (Oct 2007). Inadvertent postdialysis anticoagulation due to heparin line locks. Hemodial Int. 11:430-434. DOI.
  • Villegas-Mendez A; Montes R; Ambrose LR; Warrens AN; Laffan M; Lane DA. (May 2007). Proteolysis of the endothelial cell protein C receptor by neutrophil proteinase 3. J Thromb Haemost. 5:980-988. DOI.
  • Haynes J; Laffan M; Plaat F. (Jan 2007). Use of recombinant activated factor VII in massive obstetric haemorrhage. Int J Obstet Anesth. 16:40-49. DOI.
  • Payne EM; Brett SJ; Laffan MA. (Jul 2006). Efficacy of recombinant activated factor VII in unselected patients with uncontrolled haemorrhage: a single centre experience. Blood Coagul Fibrinolysis. 17:397-402. DOI.
  • O'Ddonnell JS; Hinkson L; McCarthy A; Manning R; Khan A; Laffan MA. (Apr 2006). Antithrombin Nagasaki (Ser 116 to Pro): a rare antithrombin variant with abnormal heparin binding presenting during pregnancy. Blood Coagul Fibrinolysis. 17:217-220. DOI.
  • Cunningham N; Laffan MA; Manning RA; O'Donnell JS. (Oct 2005). Low-density lipoprotein receptor-related protein polymorphisms in patients with elevated factor VIII coagulant activity and venous thrombosis. Blood Coagul Fibrinolysis. 16:465-468.
  • O'Donnell JS; McKinnon TA; Crawley JT; Lane DA; Laffan MA. (15 Sep 2005). Bombay phenotype is associated with reduced plasma-VWF levels and an increased susceptibility to ADAMTS13 proteolysis. Blood. 106:1988-1991. DOI.
  • Beltrán-Miranda CP; Khan A; Jaloma-Cruz AR; Laffan MA. (Jul 2005). Thrombin generation and phenotypic correlation in haemophilia A. Haemophilia. 11:326-334. DOI.
  • Laffan MA; Tait RC; Blatný J; Espersen K; Grabowska I; Loch-Bakoñska L; Pauzkowska A; Stasiak-Pikula E; et alMichalska G; Wendon J; Piotrowska K. (Apr 2005). Use of recombinant activated factor VII for bleeding in pancreatitis: a case series. Pancreas. 30:279-284.
  • Politou M; Terpos E; Anagnostopoulos A; Szydlo R; Laffan M; Layton M; Apperley JF; Dimopoulos MA; et alRahemtulla A. (Sep 2004). Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol. 126:686-689. DOI.
  • El-Shawarby SA; Margara RA; Trew GH; Laffan MA; Lavery SA. (Sep 2004). Thrombocythemia and hemoperitoneum after transvaginal oocyte retrieval for in vitro fertilization. Fertil Steril. 82:735-737. DOI.
  • Gomez K; Laffan MA; Kemball-Cook G; Pasi J; Layton M; Singer JD; Tuddenham EG; McVey JH. (Jul 2004). Two novel mutations in severe factor VII deficiency. Br J Haematol. 126:105-110. DOI.
  • Pasi KJ; Collins PW; Keeling DM; Brown SA; Cumming AM; Dolan GC; Hay CR; Hill FG; et alLaffan M; Peake IR. (May 2004). Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia. 10:218-231. DOI.
  • Laffan M; Brown SA; Collins PW; Cumming AM; Hill FG; Keeling D; Peake IR; Pasi KJ. (May 2004). The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia. 10:199-217. DOI.
  • Gomez K; Laffan MA. (Mar 2004). Hunting for the mutation in inherited thrombophilia. Blood Coagul Fibrinolysis. 15:125-127.
  • O'Connell NM; Perry DJ; Hodgson AJ; O'Shaughnessy DF; Laffan MA; Smith OP. (Dec 2003). Recombinant FVIIa in the management of uncontrolled hemorrhage. Transfusion. 43:1711-1716.
  • O'Donnell J; Manning RA; Laffan MA. (Oct 2003). Beta-adrenergic receptor polymorphisms in patients with elevated factor VIII levels with venous thrombosis. Br J Haematol. 123:139-141.
  • Laffan M; O'Connell NM; Perry DJ; Hodgson AJ; O'Shaughnessy D; Smith OP. (Jun 2003). Analysis and results of the recombinant factor VIIa extended-use registry. BLOOD COAGUL FIBRIN. 14:S35-S38.
  • O'Donnell J; Laffan MA. (Jun 2003). Dissociation of ABH antigen expression from von Willebrand factor synthesis in endothelial cell lines. Br J Haematol. 121:928-931.
  • Raja SM; Chhablani N; Swanson R; Thompson E; Laffan M; Lane DA; Olson ST. (18 Apr 2003). Deletion of P1 arginine in a novel antithrombin variant (antithrombin London) abolishes inhibitory activity but enhances heparin affinity and is associated with early onset thrombosis. J Biol Chem. 278:13688-13695. DOI.
  • Mille-Baker B; Rezende SM; Simmonds RE; Mason PJ; Lane DA; Laffan MA. (15 Feb 2003). Deletion or replacement of the second EGF-like domain of protein S results in loss of APC cofactor activity. Blood. 101:1416-1418. DOI.
  • Mumford AD; Laffan M; O'Donnell J; McVey JH; Johnson DJ; Manning RA; Kemball-Cook G. (Aug 2002). A Tyr346-->Cys substitution in the interdomain acidic region a1 of factor VIII in an individual with factor VIII:C assay discrepancy. Br J Haematol. 118:589-594.
  • O'Donnell J; Boulton FE; Laffan MA. (Jul 2002). The relationship between plasma concentration of alpha2-macroglobulin and ABO blood group. Thromb Haemost. 88:167-168.
  • O'Donnell J; Boulton FE; Manning RA; Laffan MA. (1 Feb 2002). Amount of H antigen expressed on circulating von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels. Arterioscler Thromb Vasc Biol. 22:335-341.
  • Rezende SM; Lane DA; Zöller B; Mille-Baker B; Laffan M; Dalhbäck B; Simmonds RE. (Feb 2002). Genetic and phenotypic variability between families with hereditary protein S deficiency. Thromb Haemost. 87:258-265.
  • O'Donnell J; Boulton FE; Manning RA; Laffan MA. (Feb 2002). Genotype at the secretor blood group locus is a determinant of plasma von Willebrand factor level. Br J Haematol. 116:350-356.
  • Bowcock SJ; Rassam SM; Ward SM; Turner JT; Laffan M. (Feb 2002). Thromboembolism in patients on thalidomide for myeloma. Hematology. 7:51-53. DOI.
  • Laffan MA. (Dec 2001). Fibrinogen polymorphisms and disease. Eur Heart J. 22:2224-2226. DOI.
  • O'Donnell J; Mumford AD; Manning RA; Laffan MA. (Dec 2001). Marked elevation of thrombin generation in patients with elevated FVIII:C and venous thromboembolism. Br J Haematol. 115:687-691.
  • O'Donnell J; Laffan MA. (Aug 2001). The relationship between ABO histo-blood group, factor VIII and von Willebrand factor. Transfus Med. 11:343-351.
  • Mercuri E; Cowan F; Gupte G; Manning R; Laffan M; Rutherford M; Edwards AD; Dubowitz L; et alRoberts I. (Jun 2001). Prothrombotic disorders and abnormal neurodevelopmental outcome in infants with neonatal cerebral infarction. Pediatrics. 107:1400-1404.
  • O'Donnell J; Laffan M. (2001). Elevated plasma factor VIII levels--a novel risk factor for venous thromboembolism. Clin Lab. 47:1-6.
  • O'Donnell J; Mille-Baker B; Laffan M. (Nov 2000). Human umbilical vein endothelial cells differ from other endothelial cells in failing to express ABO blood group antigens. J Vasc Res. 37:540-547.
  • Mumford AD; O'Donnell J; Gillmore JD; Manning RA; Hawkins PN; Laffan M. (Aug 2000). Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. Br J Haematol. 110:454-460.
  • Poullis M; Manning R; Laffan M; Haskard DO; Taylor KM; Landis RC. (Aug 2000). The antithrombotic effect of aprotinin: actions mediated via the proteaseactivated receptor 1. J Thorac Cardiovasc Surg. 120:370-378. DOI.
  • O'Donnell J; Mumford AD; Manning RA; Laffan M. (Jan 2000). Elevation of FVIII: C in venous thromboembolism is persistent and independent of the acute phase response. Thromb Haemost. 83:10-13.
  • Vakalopoulou S; Mille-Baker B; Mumford A; Manning R; Laffan M. (Oct 1999). Fibrinogen Bbeta14 Arg-->Cys: further evidence for a role in thrombosis. Blood Coagul Fibrinolysis. 10:403-408.
  • Mansvelt EP; Laffan M; McVey JH; Tuddenham EG. (Oct 1998). Analysis of the F8 gene in individuals with high plasma factor VIII: C levels and associated venous thrombosis. Thromb Haemost. 80:561-565.
  • Gorog DA; Rakhit R; Parums D; Laffan M; Davies GJ. (Oct 1998). Raised factor VIII is associated with coronary thrombotic events. Heart. 80:415-417.
  • Laffan M; Dawson P; Gooding RP. (Aug 1997). A comparison between the platelet activating properties of different contrast media used in radiology and MRI. Br J Radiol. 70:798-804.
  • Laffan M; Tuddenham E. (Jul 1997). Thrombophilia: an expanding group of genetic defects that predispose to thrombosis. Mol Med Today. 3:303-309. DOI.
  • O'Donnell J; Tuddenham EG; Manning R; Kemball-Cook G; Johnson D; Laffan M. (May 1997). High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. Thromb Haemost. 77:825-828.
  • Chen FE; Owen I; Savage D; Roberts I; Apperley J; Goldman JM; Laffan M. (Mar 1997). Late onset haemolysis and red cell autoimmunisation after allogeneic bone marrow transplant. Bone Marrow Transplant. 19:491-495. DOI.
  • Ireland H; Thompson E; Lane DA; Chan LC; Conard J; DeCaterina M; Rocco V; DeStefano V; et alLeone G; Finazzi G; Halil O; Laffan M; Machin S; Woodcock B. (1 Dec 1996). Gene mutations in 21 unrelated cases of phenotypic heterozygous protein C deficiency and thrombosis. THROMBOSIS AND HAEMOSTASIS. 76:867-873.
  • Simmonds RE; Ireland H; Kunz G; Lane DA; Bhavnani M; Castaman G; Hambley H; Laffan M; et alOConnor N; Sas G; Tew CJ; Walker ID. (1 Dec 1996). Identification of 19 protein S gene mutations in patients with phenotypic protein S deficiency and thrombosis. BLOOD. 88:4195-4204. Author weblink.
  • Laffan MA; Manning R. (Nov 1996). The influence of factor VIII on measurement of activated protein C resistance. Blood Coagul Fibrinolysis. 7:761-765.
  • Hay CR; Lozier JN; Lee CA; Laffan M; Tradati F; Santagostino E; Ciavarella N; Schiavoni M; et alFukui H; Yoshioka A; Teitel J; Mannucci PM; Kasper CK. (Jan 1996). Safety profile of porcine factor VIII and its use as hospital and home-therapy for patients with haemophilia-A and inhibitors: the results of an international survey. Thromb Haemost. 75:25-29.
  • Tuddenham EG; Laffan M. (19 Aug 1995). Purified factor VIII. BMJ. 311:465-466.
  • TUDDENHAM EGD; LAFFAN M. (19 Aug 1995). PURIFIED FACTOR-VIII - THEORETICAL ADVANTAGES, BUT AT A COST. BRITISH MEDICAL JOURNAL. 311:465-466. Author weblink.
  • Athanassiou P; McHale J; Dikeou S; Laffan M; Dantis P; Davies KA. (May 1995). Buerger's disease and protein S deficiency: successful treatment with prostacyclin. Clin Exp Rheumatol. 13:371-375.
  • LAFFAN MA; CHITOLIE A; OWENS D; GLEN J; LEE CA. (1 Jan 1993). ACQUIRED ANTI FACTOR-VIII INHIBITORS FOLLOWING PREGNANCY - A REPORT OF 2 CASES RESPONDING TO TREATMENT. CLINICAL AND LABORATORY HAEMATOLOGY. 15:195-202. Author weblink.
  • Laffan M; Luzzatto L. (Dec 1992). Anomalous rearrangements of the immunoglobulin heavy chain genes in human leukemias support the loop-out mechanism of class switch. J Clin Invest. 90:2299-2303. DOI.
  • SINGH AK; LAFFAN M; ERIDANI S; LUZZATTO L. (1 Jan 1991). REARRANGEMENT OF T-CELL RECEPTOR (DELTA, GAMMA AND BETA) GENES AND ITS SIGNIFICANCE IN T-CELL CHRONIC LEUKEMIAS. LEUKEMIA & LYMPHOMA. 4:17-25. Author weblink DOI.
  • Brito-Babapulle V; Crawford A; Khokhar T; Laffan M; Matutes E; Fairhead S; Catovsky D. (Jan 1991). Translocations t(14;18) and t(8;14) with rearranged bcl-2 and c-myc in a case presenting as B-ALL (L3). Leukemia. 5:83-87.
  • Marsh JC; Harhalakis N; Dowding C; Laffan M; Gordon-Smith EC; Hows JM. (Sep 1989). Recurrent graft failure following syngeneic bone marrow transplantation for aplastic anaemia. Bone Marrow Transplant. 4:581-585.
  • Foroni L; Laffan M; Boehm T; Rabbitts TH; Catovsky D; Luzzatto L. (Feb 1989). Rearrangement of the T-cell receptor delta genes in human T-cell leukemias. Blood. 73:559-565.
  • Ganly PS; Laffan MA; Owen I; Hows JM. (Aug 1988). Auto-anti-Jka in Evans' syndrome with negative direct antiglobulin test. Br J Haematol. 69:537-539.
  • Ganly PS; Isaacs JD; Laffan MA; Haslett C; Hows JM. (3 Oct 1987). Acquired factor VIII inhibitor associated with lung abscess. Br Med J (Clin Res Ed). 295:811.
  • Laffan MA; Talavera JG; Catovsky D. (Oct 1986). Hypercalcaemia in T cell acute lymphoblastic leukaemia: report of two cases. J Clin Pathol. 39:1143-1146.

Conferences

  • McKinnon TAJ; Chion ACK; Laffan MA. The effect of Von Willebrand factor glycans on the interaction with ADAMTS13. 48th Annual Meeting of the American-Society-of-Hematology. 108:484A-484A. (16 Nov 2006).
  • Scully M; Yarranton H; Liesner R; Cavenagh J; Hunt B; Benjamin S; Laffan M; Bevan D; et alMackie I; Machin SJ. The South East England thrombotic thrombocytopenic purpura registry. 48th Annual Meeting of the American-Society-of-Hematology, 9 Dec 2006 - 12 Dec 2006. 108:317A-317A. AMER SOC HEMATOLOGY (16 Nov 2006). Author weblink.
  • Watkins NA; Rankin A; Smith GA; Schaffner-Reckinger E; Kieffer N; Laffan M; Ouwehand WH. A novel inherited form of familial thrombocytopenia due to an autosomal dominant mutation in the cytoplasmic domain of the platelet beta3 integrin that is associated with the expression of activation dependent alphaIIb/beta3 epitopes. 46th Annual Scientific Meetign of the British-Society-for-Haematology, 3 Apr 2006 - 5 Apr 2006. 133:19-19. BLACKWELL PUBLISHING (1 Apr 2006). Author weblink.
  • Eccersley LRJ; Laffan MA. Lupus anticoagulant and anticardiolipin antibody testing identify populations with limited overlap. 46th Annual Scientific Meetign of the British-Society-for-Haematology, 3 Apr 2006 - 5 Apr 2006. 133:96-96. BLACKWELL PUBLISHING (1 Apr 2006). Author weblink.
  • McIntosh P; Laffan M. Soil erodibility and erosion hazard: Extending these cornerstone soil conservation concepts to headwater streams in the forestry estate in Tasmania. 10th North American Forest Soils Conference, 20 Jul 2003 - 24 Jul 2003. 220:128-139. ELSEVIER SCIENCE BV (10 Dec 2005). Author weblink DOI.
  • Mckinnon TA; Laffan MA; Riddell AF; Hann A; O'Donnell JS. Loss of terminal fucose residue expression associated with Bombay phenotype influences plasma von Willebrand factor and factor VIII antigen levels. 45th Annual Scientific Meeting of the British-Society-for-Haematology, 11 Apr 2005 - 13 Apr 2005. 129:10-11. BLACKWELL PUBLISHING (1 Apr 2005). Author weblink.
  • Mc Kinnon TA; Laffan MA; O'Donnell JS. Reduced VWF: Ag levels in Bombay phenotype are explained by a conformation-related increased susceptibility to ADAMTS-13 proteolysis. 45th Annual Scientific Meeting of the British-Society-for-Haematology. 129:45-45. (Apr 2005).
  • Cunningham N; Laffan M; Manning R; O'Donnell J. Role of low-density lipoprotein receptor-related protein (LRP) in patients with elevated FVIII : C and venous thromboembolism. 45th Annual Scientific Meeting of the British-Society-for-Haematology. 129:10-10. (Apr 2005).
  • Laffan MA; Khan AR. Elevation of coagulation factor VIII reduces the coagulation threshold and increases thrombin generation in platelet poor plasma. 45th Annual Meeting of the American-Society-of-Hematology. 102:555A-555A. (16 Nov 2003).
  • Politou M; Terpos E; Szydlo R; Laffan M; Layton M; Voskaridou E; Apperley JF; Goldman JM; et alRahemtulla A. Role of RankL, osteoprotegerin and macrophage inflammatory protein-1 alpha in monoclonal gammopathy of undetermined significance (MGUS). 45th Annual Meeting of the American-Society-of-Hematology, 6 Dec 2003 - 9 Dec 2003. 102:442A-442A. AMER SOC HEMATOLOGY (16 Nov 2003). Author weblink.
  • Ryan PJ; Harper RJ; Laffan M; Booth TH; McKenzie NJ. Site assessment for farm forestry in Australia and its relationship to scale, productivity and sustainability. International Symposium on Sustainability of Forest Soils, 18 Sep 2000 - 22 Sep 2000. 171:133-152. ELSEVIER SCIENCE BV (1 Nov 2002). Author weblink DOI.
  • KAYANO H; DYER MJS; ZANI VJ; LAFFAN MA; MATUTES E; ASOU N; KATAYAMA I; CATOVSKY D. ABERRANT REARRANGEMENTS WITHIN THE IMMUNOGLOBULIN HEAVY-CHAIN LOCUS IN HAIRY-CELL LEUKEMIA. 4th International Workshop on Hairy Cell Leukemia. 14:41-47. (Jan 1994).
Share this on Delicious
Tweet this
Digg this
Stumble this
Share this on Facebook